Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?

Slides:

Advertisements

Similar presentations

Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with Emphasis on minimizing CT to recanalization times Michael D. Hill.

Advertisements

Preventing Strokes One at a Time Acute Interventions and Management 2009.

Canadian Cardiovascular Society Antiplatelet Guidelines

Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

Rikki Weems, PGY III August 20, 2015

S TROKE M ANAGEMENT A CCORDING TO B EST P RACTICE ……..it matters…….. 1.

Upfront Combination Therapy vs Step-Up Approach for PAH:

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Target: Stroke Honor Roll

Acute Hypertension Management Optimizing Door-to-Needle Time in Ischemic Stroke.

NOACs for Cancer-Associated Thrombosis:

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

Setareh Omran, MD Vascular Neurology Fellow

US Guidelines US Guidelines Low-risk Patients.

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

PAD Patients vs Post-ACS Patients:

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Unmet Needs in the Secondary Prevention in ACS

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Select Topics in Cardiovascular Medicine

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Pulmonary Embolism Scope of the Problem Massive vs Submassive Pulmonary Embolism.

Cost Effectiveness and Optimal Outcomes in HF

Antithrombotics and PAD: A New Paradigm in Practice

The Stroke Nurse Project A community-based approach to improving the post-acute care of stroke patients. Thomas Staudacher, Pia Bader, Jürgen Kunz, Dietmar.

Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.

Selecting NOACs for High-Risk Patients

Tailoring Antiplatelet Therapy in PCI

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

The Essentials for Secondary Stroke Prevention

New Pathways in Lipid Care

CV Risk Doesn't End in the Cath Lab

AF and PCI in Practice.

What Anticoagulant Registries Are Revealing

Examining the Latest Evidence in PAH

Modified Rankin score 0-2

Practical Considerations to Extend Treatment for VTE

Taking the "Cryptogenic" Out of Cryptogenic Stroke

CV Risk Doesn't End in the Cath Lab

Overview. Complex Cases in PCI: Tailoring Antiplatelet Therapy to Improve Outcomes.

Revisiting the Pharmacoeconomics of HF

Identifying High-Risk AF Patients

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

Factor Xa Inhibitors in PAD

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

LDL Cholesterol.

Carotid Stenting in Acute Ischemic Stroke Resulting from Tandem Occlusions STEWART WEBER, MD.

Factor Xa Inhibitors in Coronary Artery Disease

Improving Adherence to Antiplatelet Therapy After an ACS Event

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Lipid Updates From Spring 2019

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Omega-3s vs Pure EPA in Clinical Practice

Updates on Dyslipidemia

(A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus.

ESC Guideline on the Management of STEMI Recommendation for DAPT

My PAH Patient.

Improving Management of Acute HTN in Patients With Stroke

Extraordinary Cases in Stroke Prevention

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?

Panelists

Program Goals

Scope of the Problem Number of Strokes Annually

Hemorrhagic vs. Ischemic Stroke

Types of Stroke US Distribution

Stroke Recurrence

Standard of Care Acute Ischemic Stroke Intravenous Thrombolysis

Paradigm Shift IV Thrombolysis for Ischemic Stroke

Guidelines for the Management of Hypertension in Patients With Ischemic Stroke/TIA

Guidelines for Lipid Management in Patients With Ischemic Stroke/TIA

Antiplatelets for Secondary Prevention After TIA or Ischemic Stroke

Completed Antiplatelet Trials

Risk Reduction for Recurrent Stroke Associated With Antiplatelet Therapy

What’s New?

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Triple Antiplatelets for Reducing Dependency After Ischemic Stroke (TARDIS)

SOCRATES

Limitations to IV Thrombolysis

Thrombectomy Trials

Pre-Hospital Stroke Evaluation

Neuroprotectants?

Public Education

Review of Antiplatelet Recommendations in US and Europe

Concluding Comments

Abbreviations

Abbreviations (cont)